DekaBank Deutsche Girozentrale Makes New $47.45 Million Investment in GT Biopharma, Inc. (NASDAQ:GTBP)

DekaBank Deutsche Girozentrale bought a new position in GT Biopharma, Inc. (NASDAQ:GTBP) during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 1,093,645 shares of the company’s stock, valued at approximately $47,449,000. DekaBank Deutsche Girozentrale owned approximately 77.02% of GT Biopharma at the end of the most recent reporting period.

GT Biopharma Stock Down 1.6 %

GT Biopharma stock traded down $0.04 during mid-day trading on Friday, hitting $2.51. The company’s stock had a trading volume of 9,200 shares, compared to its average volume of 13,515. GT Biopharma, Inc. has a 52-week low of $2.48 and a 52-week high of $10.66. The firm’s 50 day moving average is $2.97 and its 200 day moving average is $3.92.

GT Biopharma (NASDAQ:GTBP) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($2.12) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($2.70) by $0.58.

About GT Biopharma

GT Biopharma, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies.